Prothena to Report Third Quarter 2025 Financial Results on November 6
News > Health News
 
        Audio By Carbonatix
1:05 PM on Thursday, October 30
The Associated Press
DUBLIN, Ireland--(BUSINESS WIRE)--Oct 30, 2025--
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its third quarter and first nine months of 2025 financial results on Thursday November 6, 2025, after the close of the U.S. financial markets.
Consistent with past practice, the Company will not be conducting a conference call in conjunction with the financial results release on November 6.
About Prothena
Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including ATTR amyloidosis with cardiomyopathy, Alzheimer’s disease, Parkinson’s disease and a number of other neurodegenerative diseases. For more information, please visit the Company’s website at www.prothena.com and follow the Company on X (formerly Twitter) @ProthenaCorp.
View source version on businesswire.com:https://www.businesswire.com/news/home/20251030524160/en/
CONTACT: Mark Johnson, CFA, Vice President, Investor Relations
650-837-8550
KEYWORD: EUROPE IRELAND UNITED KINGDOM
INDUSTRY KEYWORD: CARDIOLOGY BIOTECHNOLOGY FDA HEALTH PHARMACEUTICAL OTHER SCIENCE RESEARCH HOSPITALS GENETICS SCIENCE CLINICAL TRIALS
SOURCE: Prothena Corporation plc
Copyright Business Wire 2025.
PUB: 10/30/2025 04:05 PM/DISC: 10/30/2025 04:05 PM
http://www.businesswire.com/news/home/20251030524160/en
 
                 
                 
                 
                 
                 
                 
                